Journal: The Febs Journal
Article Title: Butyrate suppresses mucosal inflammation in inflammatory bowel disease primarily through HDAC3 inhibition in monocytes and macrophages
doi: 10.1111/febs.70289
Figure Lengend Snippet: Butyrate reverts inflammatory mediators and enhances adherent‐invasive Escherichia coli (AIEC) phagocytosis in human THP‐1 macrophages. THP‐1 macrophages ( n = 3) were treated with butyrate in the presence or absence of lipopolysaccharide (LPS) + IFN‐γ (0.1 + 20 ng·mL −1 ) for 24 h. (A) CD40 and (B) CD80 geometric mean fluorescence intensity (gMFI) in THP‐1‐macrophages ( n = 3 or n = 5) were determined by flow cytometry. (C) Intracellular E. coli HS (commensal) and CD2‐a (AIEC) strains, normalized to control, were phagocytosed by THP‐1 macrophages treated with 2 m m butyrate (HS: n = 6; CD2‐a: n = 7). (D) mRNA levels of CD48 and MARCKS ( n = 3) were determined by RT‐qPCR. Statistical analysis: One‐way ANOVA with Bonferroni post‐test (A, B) and Wilcoxon matched‐pairs signed‐rank test (C, D). * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001.
Article Snippet: Gene expression was analyzed using TaqMan Gene Expression Assays for SLC16A1 (Hs01560299_m1), HCAR2 (Hs02341584_s1), HDAC3 (Hs00187320_m1), IRF1 (Hs00971965_m1), TFF1 (Hs00907239_m1), DUOX2 (Hs00204187_m1), and LCN2 (Hs01008571_m1), MARCKS (Hs00158993_m1), and CD48 (Hs00381156_m1) (Applied Biosystems, Waltham, MA, USA) or TaqMan primers and probes from Eurogentec (Maastricht, The Netherlands; see Table ).
Techniques: Fluorescence, Flow Cytometry, Control, Quantitative RT-PCR